Literature DB >> 33293629

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

Michael Weller1, Martin van den Bent2, Matthias Preusser3, Emilie Le Rhun4,5,6,7, Jörg C Tonn8, Giuseppe Minniti9, Martin Bendszus10, Carmen Balana11, Olivier Chinot12, Linda Dirven13,14, Pim French15, Monika E Hegi16, Asgeir S Jakola17,18, Michael Platten19,20, Patrick Roth21, Roberta Rudà22, Susan Short23, Marion Smits24, Martin J B Taphoorn13,14, Andreas von Deimling25,26, Manfred Westphal27, Riccardo Soffietti22, Guido Reifenberger28,29, Wolfgang Wick30,31.   

Abstract

In response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized the need to provide updated guidelines for the diagnosis and management of adult patients with diffuse gliomas. Through these evidence-based guidelines, a task force of EANO provides recommendations for the diagnosis, treatment and follow-up of adult patients with diffuse gliomas. The diagnostic component is based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System and the subsequent recommendations of the Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy - Not Officially WHO (cIMPACT-NOW). With regard to therapy, we formulated recommendations based on the results from the latest practice-changing clinical trials and also provide guidance for neuropathological and neuroradiological assessment. In these guidelines, we define the role of the major treatment modalities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances and cognizant that unnecessary interventions and expenses should be avoided. This document is intended to be a source of reference for professionals involved in the management of adult patients with diffuse gliomas, for patients and caregivers, and for health-care providers.

Entities:  

Mesh:

Year:  2020        PMID: 33293629      PMCID: PMC7904519          DOI: 10.1038/s41571-020-00447-z

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  118 in total

1.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Scott R Plotkin; Elizabeth Gerstner; April F Eichler; Jan Drappatz; Fred H Hochberg; Thomas Benner; David N Louis; Kenneth S Cohen; Houng Chea; Alexis Exarhopoulos; Jay S Loeffler; Marsha A Moses; Percy Ivy; A Gregory Sorensen; Patrick Y Wen; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Where does O6 -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?

Authors:  Michael Weller
Journal:  Cancer       Date:  2018-01-30       Impact factor: 6.860

3.  Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification.

Authors:  Robert H Press; Sarah L Shafer; Renjian Jiang; Zachary S Buchwald; Mustafa Abugideiri; Sibo Tian; Tiffany M Morgan; Madhusmita Behera; Soma Sengupta; Alfredo D Voloschin; Jeffrey J Olson; Shaakir Hasan; Deborah T Blumenthal; Walter J Curran; Bree R Eaton; Hui-Kuo G Shu; Jim Zhong
Journal:  Cancer       Date:  2020-04-28       Impact factor: 6.860

4.  Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

Authors:  Michael Wahl; Joanna J Phillips; Annette M Molinaro; Yi Lin; Arie Perry; Daphne A Haas-Kogan; Joseph F Costello; Manisha Dayal; Nicholas Butowski; Jennifer L Clarke; Michael Prados; Sarah Nelson; Mitchel S Berger; Susan M Chang
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

5.  Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

Authors:  Wolfgang Wick; Patrick Roth; Christian Hartmann; Peter Hau; Makoto Nakamura; Florian Stockhammer; Michael C Sabel; Antje Wick; Susanne Koeppen; Ralf Ketter; Peter Vajkoczy; Ilker Eyupoglu; Rolf Kalff; Torsten Pietsch; Caroline Happold; Norbert Galldiks; Friederike Schmidt-Graf; Michael Bamberg; Guido Reifenberger; Michael Platten; Andreas von Deimling; Christoph Meisner; Benedikt Wiestler; Michael Weller
Journal:  Neuro Oncol       Date:  2016-07-01       Impact factor: 12.300

6.  The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.

Authors:  Maarten M J Wijnenga; Pim J French; Hendrikus J Dubbink; Winand N M Dinjens; Peggy N Atmodimedjo; Johan M Kros; Marion Smits; Renske Gahrmann; Geert-Jan Rutten; Jeroen B Verheul; Ruth Fleischeuer; Clemens M F Dirven; Arnaud J P E Vincent; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

7.  Prediagnostic symptoms and signs of adult glioma: the patients' view.

Authors:  Marthe C M Peeters; Linda Dirven; Johan A F Koekkoek; Ellen G Gortmaker; Lara Fritz; Maaike J Vos; Martin J B Taphoorn
Journal:  J Neurooncol       Date:  2020-01-01       Impact factor: 4.130

8.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

Review 9.  Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.

Authors:  Anastasia Zikou; Chrissa Sioka; George A Alexiou; Andreas Fotopoulos; Spyridon Voulgaris; Maria I Argyropoulou
Journal:  Contrast Media Mol Imaging       Date:  2018-12-02       Impact factor: 3.161

10.  Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial.

Authors:  Elizabeth J Hovey; Kathryn M Field; Mark A Rosenthal; Elizabeth H Barnes; Lawrence Cher; Anna K Nowak; Helen Wheeler; Kate Sawkins; Ann Livingstone; Pramit Phal; Christine Goh; John Simes
Journal:  Neurooncol Pract       Date:  2017-05-25
View more
  197 in total

1.  Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma.

Authors:  Francesco Pasqualetti; Nicola Montemurro; Isacco Desideri; Mauro Loi; Noemi Giannini; Giovanni Gadducci; Giulia Malfatti; Martina Cantarella; Alessandra Gonnelli; Sabrina Montrone; Luca Visani; Cristian Scatena; Antonio Giuseppe Naccarato; Paolo Perrini; Carlo Gambacciani; Orazio Santonocito; Riccardo Morganti; Fabiola Paiar
Journal:  Acta Neurol Belg       Date:  2021-08-16       Impact factor: 2.396

2.  Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma.

Authors:  Nikhil Rammohan; Alexander Ho; Mohit Saxena; Amishi Bajaj; Tim J Kruser; Craig Horbinski; Alexander Korutz; Matthew Tate; Sean Sachdev
Journal:  J Neurooncol       Date:  2022-05-07       Impact factor: 4.130

Review 3.  The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.

Authors:  Huy Gia Vuong; Tam N M Ngo; Hieu Trong Le; Ian F Dunn
Journal:  J Neurooncol       Date:  2022-05-23       Impact factor: 4.130

4.  Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.

Authors:  A M Zeitlberger; P M Putora; S Hofer; P Schucht; D Migliorini; A F Hottinger; U Roelcke; H Läubli; P Spina; O Bozinov; M Weller; M C Neidert; T Hundsberger
Journal:  J Neurooncol       Date:  2022-04-29       Impact factor: 4.130

5.  The advanced development of Cx43 and GAP-43 mediated intercellular networking in IDH1 wildtype diffuse and anaplastic gliomas with lower mitotic rate.

Authors:  Aleksandrs Krigers; Patrizia Moser; Helga Fritsch; Matthias Demetz; Konstantin Brawanski; Claudius Thomé; Christian F Freyschlag
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-26       Impact factor: 4.553

6.  Cannabinoids in glioblastoma multiforme-hype or hope?

Authors:  Gary J Doherty; Bruno H R de Paula
Journal:  Br J Cancer       Date:  2021-02-24       Impact factor: 7.640

7.  Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?

Authors:  Andrew B Lassman; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

Review 8.  From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.

Authors:  Xueyuan Sun; Sevin Turcan
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

9.  Hypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI-identified tumor border indicate diffuse glioma extended tissue infiltration.

Authors:  Martina Sebök; Christiaan Hendrik Bas van Niftrik; Giovanni Muscas; Athina Pangalu; Katharina Seystahl; Michael Weller; Luca Regli; Jorn Fierstra
Journal:  Neurooncol Adv       Date:  2021-03-30

Review 10.  Accuracy of Machine Learning Algorithms for the Classification of Molecular Features of Gliomas on MRI: A Systematic Literature Review and Meta-Analysis.

Authors:  Evi J van Kempen; Max Post; Manoj Mannil; Benno Kusters; Mark Ter Laan; Frederick J A Meijer; Dylan J H A Henssen
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.